Kibow Biotech Presents Renadyl Story about Kidney Function at Harvard Medical School Probiotics Symposium

NEWTOWN SQUARE, Pa., Sept. 22, 2014 /PRNewswire/ -- The Harvard Medical School – Division of Nutrition will be hosting its annual symposium on probiotics on Sept 22 and 23 in Boston, MA. This symposium is intended to provide an overview of the latest scientific evidence related to gut microbiota and probiotics and their importance across the human life span. For more information refer to: http://harvardprobioticssymposium.org/about/  

Kibow Biotech Inc, the winner of recently held "Buzz of BIO" 2014 – International BIO conference (pipelines of promise category) at San Diego, CA, is pleased of their participation at this special event.  Kibow's abstract was also selected for a poster presentation at this event.  Kibow's poster presentation will summarize the data from its three human clinical trials with their flagship probiotic dietary supplement Renadyl™ which is targeted towards Chronic Kidney failure problems. These clinical trials were conducted at various sites in USA, Canada, Argentina and Nigeria between 2009 and 2012.

Renadyl™, a probiotic dietary supplement, is currently sold via Kibow's own online store (www.renadyl.com or www.kibow.com). This probiotic dietary supplement is known for its ability to target and help reduce the buildup of uremic toxins in the blood, thus helping to maintain healthy kidney function, via Kibow's Uremic Toxin Reduction Technology (Enteric Dialysis®). The probiotic microbial strains used in the product formulation are "Generally Recognized as Safe" (GRAS status), according to the regulations of U.S. FDA.

About Kibow Biotech:

Founded in 1997, Kibow Biotech specializes in research and development of natural probiotic/prebiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and general wellness. The Company's flagship product, Renadyl™, is currently marketed in the US and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

About Uremic Toxin Reduction Technology (Enteric Dialysis®):

Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for human product) and Azodyl (®) (veterinary formulation licensed to Vetoquinol SA) consist of a combination of three specific probiotic microbial strains. The results of a randomized, double-blind, crossover, pilot scale clinical trial completed in 2010 provided encouraging preliminary evidence that the Company's technology could be effective when the formulation is taken together with the standard care of therapy in accordance with individual patient's kidney health condition.

Investor & Media Contact: David Correale, 610-353-5130 or Email

SOURCE Kibow Biotech